Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
SUNOSI - official renal dose and monitoring check
Product / population
SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.
Renal method
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source revision
Prescribing information revised May 2026.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Keep the renal titration interval with the renal maximum
The moderate-impairment schedule uses at least seven days before an increase. This is not the general three-day titration schedule.
What to reconcile: Review the source-specific interval, maximum, indexed eGFR and monitoring together.
DailyMed / Axsome Therapeutics, Inc. · SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing. Source date: Prescribing information revised May 2026. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At eGFR 30-59 mL/min/1.73 m2, begin 37.5 mg once daily; maximum 75 mg once daily after at least 7 days if appropriate. At eGFR 15-29, use 37.5 mg once daily as both starting and maximum dose. Below 15, use is not recommended. Moderate/severe impairment increases the risk of blood-pressure, heart-rate and psychiatric adverse effects because half-life is prolonged. Control hypertension before treatment and monitor blood pressure regularly; monitor psychiatric symptoms. Do not convert a longer half-life into an unlisted dialysis or alternate-day regimen.
RDM53-official-solriamfetol-sunosi-d91445b8c4-C1 · Source locator: Sections 2.5, 5.1 and 5.2; label header and PI revision.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.